Antifungal drug resistance in Aspergillus

C.B. Moore; N. Sayers; J. Mosquera; J. Slaven; D.W. Denning

doi:10.1053/jinf.2000.0747

Antifungal drug resistance in Aspergillus

C.B. Moore, N. Sayers, J. Mosquera, J. Slaven, D.W. Denning

Division of Immunology, Immunity to Infection and Respiratory Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

This article overviews the emerging problem of antifungaldrug resistance in Aspergillus. Fluconazole and ketocona-zole (KCZ) are inactive against Aspergillus. Validation oftesting procedures for the detection of itraconazole (ITZ)resistance in Aspergillus fumigatusin 19971,2were furthervalidated with posaconazole (SCH-56592)3,4and voricona-zole (VCZ)5(Hitchcock, personal communication). Work isongoing to validate testing procedures for azoles innon-fumigatus Aspergilli.In contrast to the successful validation of azole suscep-tibility testing ofAspergillus, successful validation ofamphotericin B (AmB) testing has been problematic, withthe probable exception ofAspergillus terreus.6,7This article summarizes data from our laboratory, con-trasts it with that in the literature, and makes recommen-dations for subsequent work to further clarify thesituation. The new group of antifungal drugs, the can-dins, is not discussed and information on terbinafine istabulated only for comparison. Resistance in flucytosine is also not discussed.

Original language	Undefined
Pages (from-to)	203-220
Number of pages	18
Journal	Journal Of Infection
Volume	41
Issue number	3
DOIs	https://doi.org/10.1053/jinf.2000.0747
Publication status	Published - Nov 2000

Access to Document

10.1053/jinf.2000.0747

Cite this

@article{303a73add1504b74b21e41501923aa98,

title = "Antifungal drug resistance in Aspergillus",

abstract = "This article overviews the emerging problem of antifungaldrug resistance in Aspergillus. Fluconazole and ketocona-zole (KCZ) are inactive against Aspergillus. Validation oftesting procedures for the detection of itraconazole (ITZ)resistance in Aspergillus fumigatusin 19971,2were furthervalidated with posaconazole (SCH-56592)3,4and voricona-zole (VCZ)5(Hitchcock, personal communication). Work isongoing to validate testing procedures for azoles innon-fumigatus Aspergilli.In contrast to the successful validation of azole suscep-tibility testing ofAspergillus, successful validation ofamphotericin B (AmB) testing has been problematic, withthe probable exception ofAspergillus terreus.6,7This article summarizes data from our laboratory, con-trasts it with that in the literature, and makes recommen-dations for subsequent work to further clarify thesituation. The new group of antifungal drugs, the can-dins, is not discussed and information on terbinafine istabulated only for comparison. Resistance in flucytosine is also not discussed.",

author = "C.B. Moore and N. Sayers and J. Mosquera and J. Slaven and D.W. Denning",

year = "2000",

month = nov,

doi = "10.1053/jinf.2000.0747",

language = "Undefined",

volume = "41",

pages = "203--220",

journal = "Journal Of Infection",

issn = "0163-4453",

publisher = "W.B. Saunders Co. Ltd",

number = "3",

}

TY - JOUR

T1 - Antifungal drug resistance in Aspergillus

AU - Moore, C.B.

AU - Sayers, N.

AU - Mosquera, J.

AU - Slaven, J.

AU - Denning, D.W.

PY - 2000/11

Y1 - 2000/11

N2 - This article overviews the emerging problem of antifungaldrug resistance in Aspergillus. Fluconazole and ketocona-zole (KCZ) are inactive against Aspergillus. Validation oftesting procedures for the detection of itraconazole (ITZ)resistance in Aspergillus fumigatusin 19971,2were furthervalidated with posaconazole (SCH-56592)3,4and voricona-zole (VCZ)5(Hitchcock, personal communication). Work isongoing to validate testing procedures for azoles innon-fumigatus Aspergilli.In contrast to the successful validation of azole suscep-tibility testing ofAspergillus, successful validation ofamphotericin B (AmB) testing has been problematic, withthe probable exception ofAspergillus terreus.6,7This article summarizes data from our laboratory, con-trasts it with that in the literature, and makes recommen-dations for subsequent work to further clarify thesituation. The new group of antifungal drugs, the can-dins, is not discussed and information on terbinafine istabulated only for comparison. Resistance in flucytosine is also not discussed.

AB - This article overviews the emerging problem of antifungaldrug resistance in Aspergillus. Fluconazole and ketocona-zole (KCZ) are inactive against Aspergillus. Validation oftesting procedures for the detection of itraconazole (ITZ)resistance in Aspergillus fumigatusin 19971,2were furthervalidated with posaconazole (SCH-56592)3,4and voricona-zole (VCZ)5(Hitchcock, personal communication). Work isongoing to validate testing procedures for azoles innon-fumigatus Aspergilli.In contrast to the successful validation of azole suscep-tibility testing ofAspergillus, successful validation ofamphotericin B (AmB) testing has been problematic, withthe probable exception ofAspergillus terreus.6,7This article summarizes data from our laboratory, con-trasts it with that in the literature, and makes recommen-dations for subsequent work to further clarify thesituation. The new group of antifungal drugs, the can-dins, is not discussed and information on terbinafine istabulated only for comparison. Resistance in flucytosine is also not discussed.

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-0034523051&partnerID=MN8TOARS

U2 - 10.1053/jinf.2000.0747

DO - 10.1053/jinf.2000.0747

M3 - Article

SN - 0163-4453

VL - 41

SP - 203

EP - 220

JO - Journal Of Infection

JF - Journal Of Infection

IS - 3

ER -

Antifungal drug resistance in Aspergillus

Abstract

Access to Document

Other files and links

Cite this